Neural Therapy in Notalgia Paresthetica

Patients diagnosed with Notalgia paresthetica and who received neural therapy within the last year were retrospectively screened. In the evaluations before treatment and at the 3rd month after treatment; Numerical rating scale for pain, PainDETECT questionnaire for neuropathic pain, SF-12 for quality of life and 5-D itch scale for itch level were used.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Notalgia Paresthetica Back Pain Nervous System Diseases Neuralgia Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Pruritus Signs and Symptoms Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital

Istanbul, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

the presence of a hyperpigmented skin lesion consistent with NP
minimum 6 months for duration of disease
30-60 aged
application of neural therapy in a manner appropriate to the diagnosis

Exclusion criteria

history of previous surgery or injection in the thoracic region
presence of another treatment in the same period
presence of any cardiac or pulmonary disease, malignancy, or advanced psychiatric disease

Treatment and study plan

Neural Therapy

Other

The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.

Primary outcomes

Numeric Rating Scale for Pain

Time frame: 12 weeks after treatment

A scale between 0 and 10 was used to question the pain level.
PainDETECT Questionnaire for assessing Neuropathic pain

Time frame: 12 weeks after treatment

The questionnaire consists of 9 items and is completed by the patient (no clinical examination is required)[1][3]. There are 7 weighted sensory descriptor items (never to very strongly) and 2 items relating to spatial and temporal pain characteristics[3]. A total score of 19 or more is indicative of likely neuropathic pain.
Short Form-12 for Quality of life

Time frame: 12 weeks after treatment

The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
5-D Itch Scale

Time frame: 12 weeks after treatment

The 5-D itch scale is a 5-domain disease-specific instrument evaluating the duration, degree (severity), direction (improving, unaltered or worsening), disability (impact on sleep, leisure/social, housework/errands and school/work activities) and distribution (body part affected)

Sponsors and collaborators

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Jul 18, 2024
Registry last updated: Jul 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed